Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Zogenix
Zogenix
Controversial opioid Zohydro ER pulled from the market
Endpoints
Thu, 02/3/22 - 12:00 am
UCB Pharma
epilepsy
Zogenix
Zohydro ER
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
BioPharma Dive
Wed, 01/19/22 - 11:12 am
UCB Pharma
Zogenix
Fintepla
Dravet syndrome
Catalyst, Zogenix, Rigel and Pfizer kick off pharma's July price hikes: report
Fierce Pharma
Thu, 07/1/21 - 10:22 pm
drug pricing
Pfizer
Zogenix
Rigel Pharmaceuticals
Catalyst Pharmaceuticals
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
FDA Approves Zogenix's Drug for Rare Childhood Epilepsy
NY Times, NY
Fri, 06/26/20 - 09:46 am
FDA
Zogenix
epilepsy
Dravet syndrome
FDA pushes back decision on Zogenix epilepsy drug
BioPharma Dive
Thu, 02/27/20 - 11:41 pm
Zogenix
epilepsy
Fintepla
FDA
Dravet syndrome
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Wed, 02/26/20 - 10:26 am
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Zogenix's Positive Clinical Trial Wasn't Positive Enough
Motley Fool
Sun, 02/9/20 - 04:08 pm
Zogenix
epilepsy
Lennox-Gastaut Syndrome
clinical trials
Fintepla
GW Pharma
Epidiolex
Zogenix hands GW a win
EP Vantage
Fri, 02/7/20 - 10:32 am
Lennox-Gastaut Syndrome
clinical trials
Fintepla
Zogenix
GW Pharma
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
EP Vantage
Fri, 01/24/20 - 10:50 am
Genmab
tisotumab vedotin
cervical cancer
Zogenix
Fintepla
Lennox-Gastaut Syndrome
New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug
BioSpace
Fri, 10/25/19 - 10:42 pm
Zogenix
Fintepla
Dravet syndrome
epilepsy
Why Shares of Drugmaker Zogenix Dropped 11.4% in August
Motley Fool
Fri, 09/6/19 - 08:36 pm
Zogenix
Fintepla
Dravet syndrome
From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months
Endpoints
Mon, 08/26/19 - 09:58 am
Modis
M&A
Zogenix
F-Prime
Zogenix Prepares for Second Shot at Seizure Drug Submission
BioSpace
Tue, 07/30/19 - 04:23 pm
Zogenix
anti-seizure
FDA
Fintepla
Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Endpoints
Thu, 06/27/19 - 11:42 am
Zogenix
FDA
Dravet syndrome
Fintepla
FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
Endpoints
Mon, 04/8/19 - 11:21 pm
Zogenix
Dravet syndrome
FDA
refuse to file letters
These Epilepsy Drugmakers Are About to Brawl
Motley Fool
Thu, 07/19/18 - 11:30 pm
epilepsy
Zogenix
ZX008
GW Pharma
Epidiolex
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Xconomy
Thu, 07/12/18 - 09:59 am
Dravet syndrome
clinical trials
Zogenix
ZX008
FenPhen
GW Pharma
Epidiolex
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Tue, 07/3/18 - 11:04 am
Spark Therapeutics
Zogenix
Progenics Pharmaceuticals
SPK-8011
ZX008
Azedra
FDA
Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’
Endpoints
Tue, 02/6/18 - 09:24 am
Zogenix
FDA
epilepsy
Dravet syndrome
ZX008
breakthrough therapies
Pages
1
2
3
4
5
6
7
next ›
last »